GRIGOR GRIGORYAN: Open Payments
NPI 1205382231 · FRESNO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$559 in 24 payments from 11 companies in 2025. Trend: 2023 $1,165 · 2024 $1,268 · 2025 $559
Food & beverage: $559
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 4 | $142 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $136 |
| Stemline Therapeutics Inc. | 2 | $65 |
| E.R. Squibb & Sons, L.L.C. | 2 | $37 |
| Merck Sharp & Dohme LLC | 1 | $32 |
| RECORDATI_RARE_DISEASES_INC. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| pharmaand GmbH | 1 | $28 |
| Neuronetics, Inc. | 3 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
Products named: HETLIOZ, CAPLYTA, Orserdu, COBENFY, WELIREG, SYLVANT, ABILIFY ASIMTUFII, Rubraca.
Industry payments across CA — which companies pay providers there.
